医药魔方 / 最新资讯 / 正文

亚盛医药与MD Anderson癌症中心达成肿瘤药物开发战略合作

医药魔方 医药魔方 来源:医药魔方
2019-01-08
亚盛医药
原文

1月7日,亚盛医药与美国德克萨斯州大学MD Anderson癌症中心宣布达成一项为期5年的战略合作,双方将共同开展肿瘤领域联合研究,以推动5个在研肿瘤新药项目的临床开发。

 

MD Anderson癌症中心是全球首屈一指的综合性癌症医疗机构,在肿瘤研究与治疗方面处于世界领先地位。该项合作旨在共同开发基于亚盛医药特有的蛋白-蛋白相互作用药物发现技术平台研发的系列肿瘤新药。MD Anderson癌症中心的白血病研究团队将与亚盛医药共同合作,推进亚盛医药在研的多项细胞凋亡药物及激酶靶向药物的临床开发,这些候选项目包括Bcr-Abl抑制剂HQP1351、Bcl-2/xL抑制剂APG-1252、Bcl-2选择性抑制剂APG-2575、IAP抑制剂APG-1387和MDM2-p53抑制剂APG-115。研究将涉及单药治疗及与其它药物联合用于治疗多种恶性血液肿瘤。

 

此次合作将充分利用MD Anderson癌症中心在转化医学和临床研究方面的丰富经验,从而加速推动合作药物的临床开发。此次合作有望为治疗急性髓细胞白血病(AML)、慢性髓性白血病(CML)、急性淋巴细胞白血病(ALL)、骨髓增生性肿瘤(MPN)和骨髓纤维化等多种恶性肿瘤提供新的治疗选择。该合作将由MD Anderson癌症中心白血病系主任Hagop Kantarjian博士亲自领衔,他此前的研究曾促成20多个白血病药物获得美国食品药品监督管理局的批准。

 

 “MD Anderson癌症中心一直致力于为患者开发和提供更有效的治疗。这次合作有助于我们探索治愈癌症的新疗法。我们将对这一系列的候选药物展开研究,并对这些药物的新颖作用机制很感兴趣。”Kantarjian博士表示。

 

亚盛医药董事长杨大俊博士表示:“我们很高兴能够与MD Anderson达成此项重要合作。我们将与MD Anderson团队共同努力、密切合作,加快相关产品的临床开发,早日为全球肿瘤患者提供新的治疗选择。”

 

关于亚盛医药


亚盛医药是一家立足中国、面向全球的处于临床阶段的原创新药研发企业,致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。亚盛医药研发产品管线主要专注细胞凋亡路径关键蛋白的抑制剂,通过抑制BCL-2、IAP或MDM2-p53等,重启肿瘤细胞的凋亡程序;第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂等。公司现有8个新药项目已进入到中国、美国及澳大利亚的I-II期临床开发阶段。

 

关于MD Anderson癌症中心


德克萨斯大学MD Anderson癌症中心位于美国休斯顿市,是全球最知名的癌症中心之一,致力于为癌症患者提供护理、科研、教育和预防。该机构的唯一使命是为世界各地的患者及其家人终结癌症。MD Anderson癌症中心是美国国家癌症研究所(NCI)指定的49家综合性癌症中心之一。在《美国新闻与世界报道》的“最佳医院”调查中,MD Anderson癌症中心在癌症护理方面排名第一。自1990年此项调查开展以来,MD Anderson癌症中心每年名列全美癌症护理医院的前两名,在过去17年里曾14次排名第一。MD Anderson癌症中心获得了美国国立卫生研究院NCI的癌症中心支持拨款(P30 CA016672)。

机器翻译

On January 7, Yasheng Pharmaceutical and MD Anderson Cancer Center of the University of Texas, USA, announced a five-year strategic cooperation. Both parties will jointly conduct joint research in the field of oncology to promote the clinical development of five new cancer drug projects under development.

MD Anderson Cancer Center is the world's premier comprehensive cancer medical institution and is a world leader in cancer research and treatment.The cooperation aims to jointly develop a series of new cancer drugs based on Yasheng Pharmaceutical's unique protein-protein interaction drug discovery technology platform.The leukemia research team at MD Anderson Cancer Center will work with Yasheng Pharmaceutical to advance the clinical development of a number of apoptosis drugs and kinase-targeted drugs being developed by Yasheng Pharmaceutical. These candidates include Bcr-Abl inhibitor HQP1351, Bcl-2/XL inhibitor APG-1252, Bcl-2 selective inhibitor APG-2575, IAP inhibitor APG-1387 and MDM2-p53 inhibitor APG-115.The study will involve monotherapy and combination therapy with other agents for the treatment of a variety of hematologic malignancies.

This collaboration will make full use of the extensive experience of MD Anderson Cancer Center in translational medicine and clinical research, thereby accelerating the clinical development of collaborative drugs.This collaboration is expected to provide new therapeutic options for the treatment of various malignancies such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myeloproliferative neoplasms (MPN), and myelofibrosis.The collaboration will be led in person by Dr. Hagop Kantarjian, Director of the Leukemia Department at MD Anderson Cancer Center, whose previous research has led to more than 20 leukemia drugs being approved by the US Food and Drug Administration.

"MD Anderson Cancer Center has been working to develop and deliver more effective treatments for patients.This collaboration helps us explore new treatments for cancer.We will study this series of drug candidates and are interested in the novel mechanisms of action of these drugs.Dr. Kantarjian said.

Dr. Yang Dajun, Chairman of Yasheng Pharmaceutical, stated: "We are pleased to be able to reach this important collaboration with MD Anderson.We will work together and work closely with the MD Anderson team to accelerate the clinical development of related products and provide new treatment options for cancer patients worldwide as soon as possible."

About Yasheng Pharmaceutical

Yasheng Pharmaceutical is a China-based, global-oriented, original and innovative drug research and development company dedicated to the development of innovative drugs in the therapeutic areas of cancer, hepatitis B and aging-related diseases.The company has a self-developed protein-protein interaction targeted drug design platform.Yasheng Pharmaceutical's R & D product pipeline focuses on inhibitors of key proteins in the apoptosis pathway, restarting the apoptosis program of tumor cells by inhibiting BCL-2, IAP, or MDM2-p53, and second- and third-generation inhibitors of kinase mutants that appear in cancer therapy.The company's existing 8 new drug projects have entered Phase I-II clinical development in China, the United States and Australia.

About MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center, located in Houston, USA, is one of the most well-known cancer centers worldwide and is dedicated to providing care, research, education, and prevention to cancer patients.The sole mission of the institution is to end cancer for patients and their families around the world.MD Anderson Cancer Center is one of 49 comprehensive cancer centers designated by the National Cancer Institute (NCI).MD Anderson Cancer Center ranked first in cancer care in the "Best Hospitals" survey of the US News & World Report.Since the survey was conducted in 1990, the MD Anderson Cancer Center has been ranked in the top two cancer care hospitals in the United States each year, ranking first on 14 occasions in the past 17 years.MD Anderson Cancer Center received a Cancer Center Support Grant from the NCI, National Institutes of Health (P30 CA016672).

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号